Navigation Links
NovaBay Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results
Date:4/1/2009

3,039 2,500 Total current liabilities 4,578 4,480 Capital lease obligation - non-current 49 7 Equipment loan - non-current 497 470 Deferred revenue - non-current 4,478 1,667 Total liabilities 9,602 6,624 Stockholders' Equity: Common stock, $0.01 par value; 65,000 and 65,000 shares authorized at December 31, 2007 and December 31, 2008, respectively, 21,269 and 21,471 shares issued and outstanding at December 31, 2007 and December 31, 2008, respectively. 212 215 Additional paid-in capital 32,585 33,718 Accumulated other comprehensive income (loss) (3) - Accumulated deficit during development stage (18,474) (26,588) Total stockholders' equity 14,320 7,345 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $23,922 $13,969 CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share data) Cumulative Period from July 1, 2002 (date of development stage inception) to Year Ended December 31, December 31, 2006 2007 2008 2008 REVENUE License and collaboration revenue $1,533 $5,913 $6,722 $14,168 Total revenue
'/>"/>
SOURCE NovaBay Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. NovaBay and Galderma Enter Into Global Agreement to Develop and Commercialize NovaBays Novel Aganocide Drugs for Major Dermatological Conditions
2. NovaBay Pharmaceuticals Prices Initial Public Offering of Common Stock
3. Alseres Pharmaceuticals, Inc. Complies with NASDAQ Rule Regarding Recently Filed 10-K
4. Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
5. Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE)
6. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results
7. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results
8. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2008 Financial Results on Friday, March 13, 2009 at 8:30am EDT
9. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008
10. Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities
11. Alseres Pharmaceuticals, Inc. Announces $1 Million Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... Dec. 14 Nektar Therapeutics (Nasdaq: ... been appointed to serve on its board of ... leader with over 35 years of experience in ... brings to Nektar extensive industry perspective at an ... W. Robin, President and CEO of Nektar and ...
(Date:12/11/2009)... Corporation (Nasdaq: DNDN ) announced today that ... have exercised in full their option to purchase ... the public offering price of $24.75 per share. ... size of the offering to an aggregate of ... to receive net proceeds from the offering of ...
(Date:12/11/2009)... Algeta ASA (OSE: ALGETA), the,cancer therapeutics company, ... the,US, the Tulane Cancer Center, New Orleans, ... clinical study of Alpharadin in men with,castration-resistant ... has metastasized to the skeleton. , ... SYMptomatic Prostate CAncer) study is a,double-blind, randomized, ...
(Date:12/10/2009)... Corporation (Nasdaq: DNDN ) announced today that it ... of its common stock at a price to the ... to the underwriters a 30-day option to purchase up ... cover overallotments, if any. The offering is expected ... closing conditions. ,, J. P. Morgan Securities Inc. and ...
Breaking Biology Technology:Dennis Winger Joins Nektar Therapeutics' Board of Directors 2Dennis Winger Joins Nektar Therapeutics' Board of Directors 3Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 2Dendreon Announces Exercise of Option by Underwriters in its Common Stock Offering 3Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 3Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 4Dendreon Announces Pricing of Common Stock Offering 2Dendreon Announces Pricing of Common Stock Offering 3
... , , ... , , , , ... protein from human melanoma cell lines [1]. MIA,is expressed in and ... chondrocytes,is dependent on the differentiation status of the cells,it was also ...
... , , , ... , Abstract , ... The efficiency of the Rapid DNA Ligation Kit from,Roche Molecular ... DNA in a three-fragment assembly,DNA ligation. Sequential blunt-end and cohesive-end,ligation, including a temperature ...
... , ... , , Roche Applied Science was ... move away from the use of hazardous,radioactive isotopes. Even after 15 ... technologies, the,DIG System remains THE nonradioactive technology of,choice to label and ...
Other Biology Technology:Quantitation of the Protein MIA as a Marker for,Chondrocytes in Research Samples 2Quantitation of the Protein MIA as a Marker for,Chondrocytes in Research Samples 3Cloning Based on Efficient Three-Fragment Assembly,DNA Ligation 2Cloning Based on Efficient Three-Fragment Assembly,DNA Ligation 3Cloning Based on Efficient Three-Fragment Assembly,DNA Ligation 4The DIG System Nonradioactive and,Highly Sensitive Detection of Nucleic Acids 2The DIG System Nonradioactive and,Highly Sensitive Detection of Nucleic Acids 3The DIG System Nonradioactive and,Highly Sensitive Detection of Nucleic Acids 4The DIG System Nonradioactive and,Highly Sensitive Detection of Nucleic Acids 5
(Date:12/11/2009)... studying how bacteria under stress collectively weigh and initiate ... into how humans make strategic decisions that affect their ... , Their study, published this week in the early ... National Academy of Sciences , was accomplished when the ... describe the complex interplay of genes and proteins that ...
(Date:12/11/2009)... New discoveries about the deep ocean,s temperature variability and ... conditions. , The deep ocean is affected more by ... for more accurate predictions of factors such as sea ... surface temperatures have also been found to result in ... results in a faster transport of large quantities of ...
(Date:12/11/2009)... is a health risk but why do teens become ... evaluation for Faculty of 1000 Biology, Neil Grunberg looks ... , Grunberg describes the study, published by Natividad et ... suggests it "may have implications to help understand why ... increases the level of dopamine in the brain, a ...
Breaking Biology News(10 mins):Bacteria provide new insights into human decision making 2Bacteria provide new insights into human decision making 3Bacteria provide new insights into human decision making 4Bacteria provide new insights into human decision making 5New discoveries could improve climate projections 2TBGH Report on Status of Diabetes in Texas Indicates Growing Severity of Problem and Higher Cost of Care Than National Average 57487 1TBGH Report on Status of Diabetes in Texas Indicates Growing Severity of Problem and Higher Cost of Care Than National Average 57487 2TBGH Report on Status of Diabetes in Texas Indicates Growing Severity of Problem and Higher Cost of Care Than National Average 57487 3TBGH Report on Status of Diabetes in Texas Indicates Growing Severity of Problem and Higher Cost of Care Than National Average 57487 4Swine Flu Loves a Crowd 57482 1Swine Flu Loves a Crowd 57482 2Swine Flu Loves a Crowd 57482 3Swine Flu Loves a Crowd 57482 4Valeant Pharmaceuticals to Present at the UBS Global Life Sciences Conference 57478 1Valeant Pharmaceuticals to Present at the UBS Global Life Sciences Conference 57478 2
... In order to increase productivity, forest practices have become ... 800% in the southeastern United States from 1990 to ... exceeds the forest area fertilized in the rest of ... practices, including fertilization, may negatively impact water quality in ...
... a host of threats that can result in fetal/neonatal ... issue of the American Journal of Obstetrics & Gynecology, ... the Drexel University College of Medicine found that genital ... 23% of neonates born between 23 and 32 weeks ...
... identified a key factor that determines the ability of ... respiratory tracta necessary step for sustaining spread between people. ... of Nature Biotechnology and funded by the National Institutes ... H5N1 avian flu virus currently circulating in birds would ...
Other Biology News:Will intensive forest practices impact water quality? 2Bacterial infections in premature babies more common than previously realized 2Study of sugars on cell surface identifies key factor in flu infection 2Study of sugars on cell surface identifies key factor in flu infection 3
Maxi 14 Hybridization Oven. 14 bottle (35 mm) rotisserie + shaker tray available for simultaneous use. Includes linear and orbital shaker trays, 4 medium bottles, pack of mesh, bottle gripper and d...
Shake 'n' Stack Oven - New Model (includes 10 bottle capacity rotisserie, adjustable feet, drip tray, manual PLUS Shaker Platform)...
... Expansion Kit - Monolayer Plus is a system ... as a monolayer in a serum-free environment. The ... Supplement, which has been optimized for neural stem ... (1996) Genes & Development 10 :3129). Human ...
... DNase is a preparation of deoxyribonuclease ... DNA to produce 3-hydroxyl oligonucleotides. This ... applications where maintaining the integrity of ... qualified for use with the Core ...
Biology Products: